Omeben 40 mg (Capsule (Enteric Coated))

Unit Price: ৳ 8.00 (3 x 10: ৳ 240.00)

Strip Price: ৳ 80.00

Medicine Details

Gastric and duodenal ulcer
NSAID-associated duodenal and gastric ulcer
As prophylaxis in patients with a history of NSAID-associated duodenal and gastric ulcer
Gastro-esophageal reflux disease
Long-term management of acid reflux disease
Acid-related dyspepsia
Severe ulcerating reflux esophagitis
Prophylaxis of acid aspiration during general anesthesia
Zollinger-Ellison syndrome
Helicobacter pylori-induced peptic ulcer

Inhibitor of gastric acid secretion
Blocker of hydrogen-potassium-adenosine triphosphatase (H+/K+ ATPase) enzyme system
Onset of antisecretory effect within one hour
Maximum effect occurring within two hours
Inhibition of secretion lasts up to 72 hours
Gradual return of secretory activity over 3 to 5 days after discontinuation

20 mg once daily for benign gastric and duodenal ulcer
20 mg once daily for NSAID-associated duodenal or gastric ulcer
20 mg once daily for gastro-esophageal reflux disease
10-20 mg daily for long-term management of acid reflux disease
10-20 mg once daily for acid-related dyspepsia
40 mg on the preceding evening and 2-6 hours before surgery for prophylaxis of acid aspiration
Initially 60 mg once daily for Zollinger-Ellison syndrome
Omeprazole is recommended at a dose of 20 mg twice daily in association with antimicrobial agents for Helicobacter pylori eradication regimen
10-20 mg once daily for severe ulcerating reflux esophagitis in pediatric use
40 mg intravenously for prophylaxis of acid aspiration
40 mg intravenously for duodenal ulcer, gastric ulcer, or reflux esophagitis
Initial intravenous dose of 60 mg daily for Zollinger-Ellison syndrome
IV infusion over 20-30 minutes or more
Oral and IV administration instructions

Decreased intragastric acidity affecting the absorption of ketoconazole
Metabolism through cytochrome P450 affecting the elimination of diazepam, phenytoin, and warfarin
Monitoring and potential dose reduction of warfarin or phenytoin
Increased plasma concentrations during concomitant administration with clarithromycin
No evidence of interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, cyclosporin, lidocaine, quinidine, estradiol, amoxycillin, or antacids
No effect on absorption by alcohol or food
No evidence of interaction with piroxicam, diclofenac, or naproxen
Increased bioavailability of digoxin during simultaneous treatment with Omeben

Mild and reversible adverse reactions
Skin rash, urticaria, and pruritus
Photosensitivity, bullous eruption, erythema multiforme, angioedema, and alopecia
Diarrhoea and headache
Gastrointestinal reactions including constipation, nausea/vomiting, flatulence, and abdominal pain
Dry mouth, stomatitis, and candidiasis
Paraesthesia, dizziness, light headedness, and feeling faint
Somnolence, insomnia, and vertigo
Reversible mental confusion, agitation, depression, and hallucinations
Arthritic and myalgic symptoms
Blurred vision, taste disturbance, peripheral oedema, increased sweating, gynaecomastia, and hematological changes
Hepatic effects including hepatitis, interstitial nephritis, and hepatic failure
Increases in liver enzymes

No adverse effects on pregnancy or on the health of the fetus/newborn child based on epidemiological studies
Safe to use during pregnancy
Discontinuation of breastfeeding if essential use of Omeprazole is considered
Safety and effectiveness not established in pediatric patients less than 18 years of age